Fosamax (Alendronate) Cost, Compounded Equivalents, and Insurance Coverage: A Women's Guide

What Is Alendronate and Why Does It Matter to Women Specifically?

Alendronate is the generic name for the branded bisphosphonate Fosamax. It is the most widely prescribed medication for osteoporosis in the United States, and women make up the overwhelming majority of people who take it. That is not a coincidence.

After menopause, estrogen withdrawal accelerates bone resorption dramatically. Research published in the Journal of Bone and Mineral Research estimates that women lose between 1% and 3% of bone mineral density per year in the first decade after menopause, a rate roughly four times faster than age-matched men. Alendronate works by binding to hydroxyapatite in bone and inhibiting osteoclast-mediated resorption, slowing that loss.

Why the Sex-Specific Biology Matters for Dosing

The standard postmenopausal osteoporosis dose is 70 mg once weekly or 10 mg daily. ACOG Practice Bulletin 129 on osteoporosis confirms these doses for postmenopausal women and notes that bisphosphonates remain first-line pharmacotherapy. The 35 mg once-weekly formulation is used for postmenopausal osteoporosis prevention (T-score between -1.0 and -2.5 with risk factors) and for glucocorticoid-induced osteoporosis in premenopausal women.

Renal clearance of alendronate is reduced in women with an estimated GFR below 35 mL/min, making it contraindicated at that threshold. Because women develop chronic kidney disease at different rates and ages than men, your clinician should check a basic metabolic panel before starting.

Life-Stage Snapshot

• Reproductive years (18-40): Alendronate is occasionally used for glucocorticoid-induced bone loss or in women with premature ovarian insufficiency. Effective contraception is mandatory. See the pregnancy section below.
• Perimenopause (typically 40-51): Bone loss accelerates in the 2-3 years before the final menstrual period. The Menopause Society (formerly NAMS) 2023 position statement on nonhormonal management of menopause notes that bisphosphonates can be initiated when DXA confirms osteoporosis or high FRAX risk.
• Postmenopause: This is the primary indication. DXA-confirmed osteoporosis (T-score at or below -2.5) or fragility fracture are standard starting criteria.
• Post-treatment (drug holidays): After 5 years of oral bisphosphonate therapy, guidelines recommend reassessing fracture risk before continuing. Women at lower risk may take a drug holiday; those with a T-score below -2.5 at the hip typically continue.

The Real Cash-Pay Cost of Generic Alendronate

Generic alendronate is one of the cheapest osteoporosis drugs available. Full stop.

A 4-tablet supply of 70 mg alendronate (one month of once-weekly dosing) costs approximately $10-$18 at major U.S. Pharmacy chains with a GoodRx or similar discount coupon. GoodRx pricing data for alendronate 70 mg (4 tablets, 30-day supply) shows a range of roughly $10 to $20 at Walmart, Costco, and Kroger pharmacies as of early 2026. Exact prices shift by ZIP code and pharmacy contract, so verify before you fill.

Where to Get the Lowest Price

| Pharmacy Option | Estimated Monthly Cost | Notes | |---|---|---| | Walmart $4/$10 generic list | ~$4-$10 | Confirm alendronate 70 mg is on current list | | GoodRx coupon at chain pharmacy | ~$10-$18 | Print or show app at counter | | Costco pharmacy (members) | ~$8-$12 | No membership required for pharmacy in most states | | Mark Cuban's Cost Plus Drugs | ~$6-$12 + dispensing fee | Ships to most states | | Manufacturer (Merck) program | Variable | Fosamax brand rarely stocked; generic programs dominate |

Does Merck Offer a Fosamax Coupon?

Merck no longer actively markets branded Fosamax in the U.S. Because the patent expired and generics now dominate. There is no widely available branded Fosamax manufacturer coupon program as of 2026. If a coupon site claims otherwise, verify the program is current before printing it. Programs change frequently, and stale coupon links are common on health websites.

For women who are uninsured or underinsured, the better route is generic alendronate through Cost Plus Drugs or a GoodRx discount rather than hunting for a branded coupon.

Is There a Compounded Equivalent to Fosamax?

No FDA-approved compounded alendronate product exists, and there is a specific reason you should know about this.

Here is a practical framework for thinking through whether compounding makes sense for any osteoporosis drug: compounding is generally justified when (1) a commercially available product is unavailable or causes specific excipient allergies, (2) a patient-specific dose is needed that no commercial form provides, or (3) a route of administration is required that no commercial formulation covers. Alendronate fails all three tests for the vast majority of women.

Why Compounding Adds No Value Here

Generic alendronate is consistently available from multiple manufacturers. The price is already at or near the floor of what any compounding pharmacy could match once you add the compounding fee (typically $30-$80 per month at most 503A compounding pharmacies). A compounded alendronate preparation would cost more, not less, and would carry the added risk of not meeting the bioavailability standards that FDA approval requires.

The FDA's 503A compounding framework requires that compounded preparations not be essentially a copy of a commercially available drug. A generic alendronate 70 mg tablet is commercially available and inexpensive, so a compounding pharmacist preparing an identical dose would technically be in tension with this requirement.

What About Alendronate IV or Liquid Forms?

Intravenous bisphosphonates do exist, but the IV bisphosphonate of choice is zoledronic acid (Reclast), given once yearly. An oral alendronate liquid (Binosto, an effervescent tablet) is FDA-approved for women who cannot tolerate standard tablets due to esophageal issues. If you need a liquid formulation, ask your clinician about Binosto rather than a compounded liquid.

How Insurance Covers Alendronate

Alendronate's generic status makes insurance coverage straightforward in most plans.

Commercial Insurance

Most commercial plans place generic alendronate on Tier 1 (the lowest-cost tier), meaning your copay may be $0 to $10. If your plan places it on Tier 2, ask your pharmacist to run a GoodRx price, because the coupon price frequently beats the insured copay.

Medicare Part D

CMS data shows that alendronate is one of the most commonly covered generic drugs across Medicare Part D formularies. During the standard benefit phase, most Part D enrollees pay $0-$5 per fill. If your plan denies it, your clinician can submit a formulary exception citing osteoporosis diagnosis codes (M80.x, M81.x).

Medicaid

All state Medicaid programs cover generic alendronate. Prior authorization is not typically required, though some states require a DXA-confirmed diagnosis code on the claim. If your pharmacy says it is not covered, ask the pharmacist to resubmit with the correct ICD-10 code from your provider.

What to Do If Insurance Denies Coverage

1. Ask the pharmacist to resubmit with the osteoporosis ICD-10 code from your clinician.
2. Request a formulary exception through your plan's member services line; your clinician's office can often do this by fax.
3. Use GoodRx or Cost Plus Drugs as a cash-pay fallback. At ~$15/month, paying out-of-pocket is feasible for most budgets.
4. Ask your clinician if your state has a State Pharmaceutical Assistance Program (SPAP) that supplements Medicare Part D.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is mandatory reading if you are in your reproductive years or are not certain your fertility phase is complete.

Pregnancy: Category D. Avoid.

Alendronate is classified as FDA Pregnancy Category D, meaning there is positive evidence of human fetal risk. Bisphosphonates incorporate into fetal bone and can persist there for years. Animal studies show skeletal malformations at doses equivalent to human therapeutic levels. Human case reports of inadvertent bisphosphonate exposure in pregnancy document neonatal hypocalcemia and low birth weight in some cases.

If there is any chance you could become pregnant, you and your clinician must discuss effective contraception before starting alendronate. The drug's long skeletal half-life (estimated at more than 10 years) means that bone-incorporated alendronate may still be present during a subsequent pregnancy even after you stop taking it. A 2021 review in the American Journal of Obstetrics and Gynecology summarized case series data and concluded that preconception bisphosphonate exposure carries uncertain but non-zero fetal risk, and that decisions about timing pregnancies after bisphosphonate use require individualized counseling.

For premenopausal women taking alendronate for glucocorticoid-induced osteoporosis or premature ovarian insufficiency, the conversation with your clinician should explicitly cover:

• Duration of treatment before attempting conception
• Whether a drug holiday is appropriate before a planned pregnancy
• Alternative agents with shorter half-lives (e.g., raloxifene, denosumab) if pregnancy is likely within the next 2-3 years (noting raloxifene is also teratogenic)

Lactation

The FDA prescribing information states that it is not known whether alendronate is excreted in human breast milk. Because of its potential to affect neonatal bone development, most clinicians advise against use during breastfeeding unless the clinical need clearly outweighs the theoretical risk. Postpartum bone loss (lactation-associated osteoporosis) is a real but rare condition; treatment decisions in that setting should happen with a specialist.

Contraception Requirements

No specific contraceptive method is mandated by alendronate labeling the way it is with some teratogens (e.g., isotretinoin's iPLEDGE program). However, given the Category D classification and the drug's long half-life, any woman of reproductive age taking alendronate should use effective contraception. Discuss your specific method with your clinician.

Who Is This Drug Right For, and Who Should Look Elsewhere

The decision to start alendronate is not purely about cost. Life stage and comorbidity matter.

Women Who Are Good Candidates

• Postmenopausal women with a DXA T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip. The 2020 American Association of Clinical Endocrinologists/American College of Endocrinology guidelines recommend pharmacotherapy for postmenopausal women with osteoporosis and at high fracture risk.
• Women with a prior fragility fracture (wrist, hip, or vertebral fracture from minimal trauma) regardless of T-score.
• Women on long-term glucocorticoids (prednisone 7.5 mg/day or more for 3 or more months) at any age.
• Women with FRAX 10-year probability of major osteoporotic fracture at or above 20%, or hip fracture probability at or above 3%.

Women Who Need a Different Approach

• Pregnant women or those planning pregnancy within 1-2 years. Bisphosphonates are not the right choice. Discuss calcium, vitamin D, and weight-bearing exercise with your OB.
• Women with GFR <35 mL/min. Alendronate is contraindicated; zoledronic acid or denosumab with renal-dose adjustments may be considered by a specialist.
• Women with esophageal abnormalities (stricture, achalasia, inability to sit upright for 30 minutes after dosing). Binosto (effervescent tablet) or an IV bisphosphonate may be more appropriate.
• Women with active upper GI disease or those taking NSAIDs heavily. GI tolerability is the primary reason women discontinue alendronate. Up to 15-20% report GI side effects, and switching to once-weekly dosing or Binosto improves tolerability for many.
• Women who have already completed 5 years of bisphosphonate therapy with a stable T-score above -2.5. A drug holiday is appropriate in this group per The Menopause Society's guidance on bisphosphonate drug holidays.

Female-Relevant Conditions Alendronate Intersects

PCOS and Bone Health

Women with polycystic ovary syndrome frequently have irregular ovulation and low estrogen exposure, which can affect bone density. Some studies suggest bone mineral density in PCOS is preserved or even increased due to androgen excess, but women with PCOS who develop hypothalamic amenorrhea from restrictive eating are at genuine fracture risk. Alendronate is not typically first-line in this population; estrogen restoration is preferred.

Premature Ovarian Insufficiency (POI)

Women diagnosed with POI before age 40 lose bone at an accelerated rate. ACOG recommends hormone therapy as the primary bone-protective strategy for women with POI until at least age 50, with bisphosphonates reserved for cases where hormone therapy is contraindicated or insufficient.

Postpartum and Lactation-Associated Osteoporosis

This rare condition causes severe vertebral fractures, usually in the third trimester or early postpartum period. Bisphosphonate use in this context is off-label and should be managed by a metabolic bone specialist, not initiated based on general osteoporosis guidelines.

Glucocorticoid-Induced Osteoporosis in Women with Autoimmune Disease

Women with rheumatoid arthritis, lupus, inflammatory bowel disease, and asthma are disproportionately affected by glucocorticoid-induced bone loss. Alendronate 35 mg weekly is specifically FDA-approved for this indication in premenopausal women (with contraception in place) and at 70 mg weekly in postmenopausal women.

The Evidence Base: What the Trials Actually Showed

The Fracture Intervention Trial (FIT) is the cornerstone study for alendronate in women. FIT enrolled 6,459 postmenopausal women aged 55-81 with low femoral neck bone density and followed them for up to 4 years, finding a 47% reduction in hip fracture risk and a 55% reduction in vertebral fracture risk in the alendronate group versus placebo. The trial enrolled women only. That matters: the efficacy data for alendronate in women is direct, not extrapolated from mixed-sex studies.

A Cochrane systematic review of bisphosphonates for postmenopausal osteoporosis (2020) confirmed that alendronate reduces vertebral fractures by approximately 45% and non-vertebral fractures by approximately 16% compared with placebo.

One honest caveat: most FIT participants were white women. Data on fracture reduction in Black, Latina, and Asian women taking alendronate is thinner, drawn largely from subgroup analyses rather than primary trials. A 2019 analysis in JAMA Internal Medicine noted that Black women have lower rates of osteoporosis diagnosis and bisphosphonate prescribing despite carrying meaningful fracture risk, a gap that reflects systemic under-treatment rather than a difference in drug efficacy. If you are a woman of color with fracture risk factors, these data gaps should not delay appropriate treatment.

Practical Takeaways for Getting Alendronate at the Lowest Cost

Because the generic is already inexpensive, the access problem for most women is not finding a compounded version. The access problem is either navigating an insurance denial or not knowing that the drug costs $15 cash-pay.

Steps in order of priority:

1. Ask your pharmacist to check GoodRx or Blink Health before running your insurance. The coupon price frequently beats the insured copay.
2. Confirm the ICD-10 code is on the claim. M81.0 (age-related osteoporosis without current pathological fracture) or M80.00 (with fracture) are the most common. A missing or wrong code is the most common reason for a technical denial.
3. Check Cost Plus Drugs (costplusdrugs.com) for the current cash price; it has been as low as $6 for a 30-day supply.
4. If your plan denies, appeal with a letter of medical necessity from your clinician citing your DXA result and FRAX score. Most denials for a Tier 1 generic are administrative errors.
5. Do not pursue a compounded alendronate. It costs more, has no regulatory equivalence guarantee, and solves a problem that does not exist given the ~$15 generic price.

All prices and program details listed here reflect conditions as of early 2026. Pharmacy pricing and patient assistance programs change frequently. Verify the current price directly at the pharmacy counter or on the drug pricing platform before you fill.